SAB Biotherapeutics (SABS) Net Margin (2021 - 2025)
Historic Net Margin for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to 27873.57%.
- SAB Biotherapeutics' Net Margin changed N/A to 27873.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 62032.46%, marking a year-over-year increase of 650447400.0%. This contributed to the annual value of 2579.03% for FY2024, which is 6945300.0% down from last year.
- Per SAB Biotherapeutics' latest filing, its Net Margin stood at 27873.57% for Q3 2025.
- In the past 5 years, SAB Biotherapeutics' Net Margin ranged from a high of 27873.57% in Q3 2025 and a low of 9934.52% during Q4 2024
- Its 5-year average for Net Margin is 1101.79%, with a median of 150.79% in 2021.
- Its Net Margin has fluctuated over the past 5 years, first tumbled by -79709200bps in 2023, then skyrocketed by 185065100bps in 2025.
- SAB Biotherapeutics' Net Margin (Quarter) stood at 104.46% in 2021, then plummeted by -249bps to 364.42% in 2022, then tumbled by -1956bps to 7493.75% in 2023, then tumbled by -33bps to 9934.52% in 2024, then surged by 381bps to 27873.57% in 2025.
- Its last three reported values are 27873.57% in Q3 2025, 15718.81% for Q2 2025, and 7470.38% during Q1 2025.